Separately, Zacks Investment Research upgraded Rexahn Pharmaceuticals from a hold rating to a buy rating and set a $0.25 price target for the company in a report on Friday, August 12th.
Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.1705 on Thursday. The stock has a 50 day moving average price of $0.22 and a 200-day moving average price of $0.27. Rexahn Pharmaceuticals has a 12 month low of $0.16 and a 12 month high of $0.52. The stock’s market cap is $36.37 million.
Rexahn Pharmaceuticals (NYSE:RNN) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.01. On average, analysts expect that Rexahn Pharmaceuticals will post ($0.07) EPS for the current year.
A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Vanguard Group Inc. raised its stake in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned about 2.30% of Rexahn Pharmaceuticals worth $1,232,000 as of its most recent SEC filing.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.